Sanofi-Aventis, Paul and Mira Sorvino launch ‘Diabetes Co-Stars’ program
BRIDGEWATER, N.J. Sanofi-Aventis has tapped actors Paul and Mira Sorvino to launch an awareness program aimed to help people living with diabetes and those who support them.
The "Diabetes Co-Stars" program provides family and friends of diabetics with advice on lifestyle choices, healthy cooking, promoting physical activity and treatment options including insulin, Sanofi-Aventis said. DiabetesCoStars.com provides links to the Sanofi-Aventis diabetes social media pages, including Facebook and Twitter.
The website also provides a look into Paul Sorvino’s life with Type 2 diabetes and how he manages his condition. Sorvino was diagnosed in 2006 with the condition, and at the direction of his doctor, he began taking prescription oral diabetes medications, including Sanofi-Aventis’ diabetes drug Lantus. While treatment and lifestyle changes continue to help Sorvino on his diabetes journey, having support from his daughter, Mira, also has helped Sorvino to make the right decisions.
"’Diabetes Co-Stars’ will help inspire people to find support for their diabetes journey," Sorvino said. "After my diagnosis of Type 2 diabetes, I was completely overwhelmed. I realized the importance of learning how to manage the condition, and that I don’t have to do it alone. I also worked with my doctor to discuss lifestyle changes and to find a treatment plan that works for me."
Price Chopper expands Diabetes AdvantEdge program with free offerings
SCHENECTADY, N.Y. Insulin-dependent diabetics will be eligible to receive free syringes and pen needles from Price Chopper, the Northeast supermarket chain said.
Price Chopper said the expansion of its Diabetes AdvantEdge program meant that it could serve 100% of the population that manages diabetes with increased access to medication, supplies, support and information, as well as education on food, nutrition and diabetes management.
“Diabetes AdvantEdge has been so well-received by those managing diabetes, as well as members of the healthcare community, that several chain drug stores have attempted to follow suit,” Price Chopper VP pharmacy Vincent Mainella said. “As a supermarket, however, we differentiate ourselves by providing a wide variety of fresh and packaged foods coupled with open access to our health professionals, registered dietitians and nutrition specialists.”
Prestige Brands to acquire Blacksmith Brands for $190 million
IRVINGTON, N.Y. Prestige Brands on Monday announced that it has entered into a definitive agreement to acquire 100% of the stock of Blacksmith Brands for $190 million in cash. Blacksmith manages five over-the-counter brands, including Efferdent, Effergrip, PediaCare, Luden’s and NasalCrom.
With the addition of these five brands, OTC products in the Prestige portfolio now account for 75% of revenues and an even greater percentage of brand contribution.
“Strategic acquisitions in the OTC market are core to our shareholder value creation strategy,” stated Matthew Mannelly, Prestige CEO. "We are strengthening Prestige’s position in key categories with the additions of Efferdent, PediaCare and Luden’s. These three scale brands compete in attractive categories we know well.”
The transaction is subject to customary closing conditions, including clearance under the Hart-Scott Rodino Antitrust Improvements Act of 1976, and is expected to close during fourth quarter 2010.
In June, Blacksmith Brands had voluntarily recalled all lots of its four children’s products in the PediaCare line, which were being manufactured for Blacksmith Brands by McNeil Consumer Healthcare at McNeil’s now-closed Fort Washington, Pa., plant. That recall was not initiated as a result of any consumer reports of adverse events, and no consumer complaints have been received about the safety or purity of the products, the company stated at the time.
In line with the announcement of the Blacksmith transaction, Prestige also announced the divestiture of its Cutex line of nail polish removers, the largest remaining product in its personal care segment. The sale to Arch Equity Partners of St. Louis was effective Sept. 1.